Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 6/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | STAMBP | O95630 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8950128 | 0.84 | EGLN2 (0.36) | EGLN2 | |
| SCHEMBL1485662 | 0.79 | SRC (0.35) | PIK3CAKDRDGAT1NR3C2 | |
| SCHEMBL1431710 | 0.79 | KDM4E (0.36) | DGAT1NR3C2 | |
| SCHEMBL8950348 | 0.79 | HTR4 (0.41) | BRD4RETKDR | |
| SCHEMBL8954913 | 0.79 | BRD4 (0.40) | BRD4 | |
| SCHEMBL12410910 | 0.79 | NPSR1 (0.33) | KDRDGAT1EGLN2NR3C2 | |
| SCHEMBL12410702 | 0.78 | PIK3CA (0.39) | PIK3CARETKDRNR3C2 | |
| SCHEMBL18018738 | 0.78 | DGAT1 (0.33) | PIK3CADGAT1NR3C2 | |
| Lithium SCHEMBL30893549 | 0.78 | KDM4E (0.36) | DGAT1NR3C2 | |
| SCHEMBL8950151 | 0.78 | MAOB (0.39) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CA 637/4885BRD4 789/4885PDE10A 788/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CA 637/4885BRD4 789/4885PDE10A 788/4885 |
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | PIK3CA 881/4885BRD4 4607/4885PDE10A 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.